These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7894259)

  • 1. CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia.
    Levine J; Goldberger I; Rapaport A; Schwartz M; Schield C; Elizur A; Belmaker RH; Shapiro J; Agam G
    Eur Neuropsychopharmacol; 1994 Dec; 4(4):487-90. PubMed ID: 7894259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled trials of inositol in psychiatry.
    Levine J
    Eur Neuropsychopharmacol; 1997 May; 7(2):147-55. PubMed ID: 9169302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of inositol treatment in chronic schizophrenia.
    Levine J; Umansky R; Ezrielev G; Belmaker RH
    Biol Psychiatry; 1993 Apr 15-May 1; 33(8-9):673-5. PubMed ID: 8329500
    [No Abstract]   [Full Text] [Related]  

  • 4. Inositol treatment raises CSF inositol levels.
    Levine J; Rapaport A; Lev L; Bersudsky Y; Kofman O; Belmaker RH; Shapiro J; Agam G
    Brain Res; 1993 Nov; 627(1):168-70. PubMed ID: 8293297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gas chromatographic-mass spectrometric determination of myo-inositol in human cerebrospinal fluid.
    Swahn CG
    J Neurochem; 1985 Aug; 45(2):331-4. PubMed ID: 4009166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid inositol monophosphatase: elevated activity in depression and neuroleptic-treated schizophrenia.
    Atack JR; Levine J; Belmaker RH
    Biol Psychiatry; 1998 Sep; 44(6):433-7. PubMed ID: 9777174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients.
    Heikkilä L; Rimón R; Terenius L
    Psychiatry Res; 1990 Dec; 34(3):229-36. PubMed ID: 1706098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
    Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL
    Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, controlled trial of inositol treatment of depression.
    Levine J; Barak Y; Gonzalves M; Szor H; Elizur A; Kofman O; Belmaker RH
    Am J Psychiatry; 1995 May; 152(5):792-4. PubMed ID: 7726322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine-serotonin relationship in clozapine response.
    Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inositol treatment of autism.
    Levine J; Aviram A; Holan A; Ring A; Barak Y; Belmaker RH
    J Neural Transm (Vienna); 1997; 104(2-3):307-10. PubMed ID: 9203092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial.
    Barak Y; Levine J; Glasman A; Elizur A; Belmaker RH
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 May; 20(4):729-35. PubMed ID: 8843494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF inositol does not predict antidepressant response to inositol. Short communication.
    Levine J; Kurtzman L; Rapoport A; Zimmerman J; Bersudsky Y; Shapiro J; Belmaker RH; Agam G
    J Neural Transm (Vienna); 1996; 103(12):1457-62. PubMed ID: 9029413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inositol treatment in psychiatry.
    Benjamin J; Agam G; Levine J; Bersudsky Y; Kofman O; Belmaker RH
    Psychopharmacol Bull; 1995; 31(1):167-75. PubMed ID: 7675981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.
    Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ
    Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127
    [No Abstract]   [Full Text] [Related]  

  • 17. A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: II. Correlations with psychopathology.
    Issa F; Kirch DG; Gerhardt GA; Bartko JJ; Suddath RL; Freedman R; Wyatt RJ
    Psychiatry Res; 1994 Jun; 52(3):251-8. PubMed ID: 7991719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment.
    Heikkilä L
    Schizophr Res; 1993 Jan; 8(3):273-7. PubMed ID: 8094631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome.
    Nemeroff CB; Bissette G; Widerlov E; Beckmann H; Gerner R; Manberg PJ; Lindstrom L; Prange AJ; Gattaz WF
    J Neuropsychiatry Clin Neurosci; 1989; 1(1):16-20. PubMed ID: 2577718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.